Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Tumor-Agnostic 6Sarcoma 4Genitourinary 2Breast 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Head & Neck 1Endocrine 1Classical hematology 1

Conditions

Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Doxorubicin 4Sunitinib 3Radiosurgery 3Everolimus 3pembrolizumab 2exemestane 2Tamoxifen 2Specimen Handling 2Octreotide 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Filgrastim 2Biopsy 2Bevacizumab 23-Iodobenzylguanidine 2tislelizumab 1surufatinib 1romidepsin 1regorafenib 1penpulimab 1pasireotide 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1lanreotide 1ganitumab 1folfirinox 1fludarabine phosphate 1epothilone B 1entrectinib 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × regorafenib × Endocrine × Clear all
NCT03475953 2023-03-03

REGOMUNE

Institut Bergonié

Phase 1/2 Unknown
747 enrolled
BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡